Expertise in
6
conditions

Dr. Delphine W. Ong

Oncology
Dignity Health Mercy Medical Group
9394 Big Horn Blvd Fl 2, 
Elk Grove, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Expertise in
6
conditions
Dignity Health Mercy Medical Group
9394 Big Horn Blvd Fl 2, 
Elk Grove, CA 

Overview

Delphine Ong is an Oncologist practicing medicine in Elk Grove, California.

Dr. Ong is highly rated in 6 conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Breast Cancer, Inflammatory Breast Cancer, and Classical Hodgkin Lymphoma.

She is actively involved in clinical research, participating in 5 clinical trials. Dr. Ong is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Dignity Health Mercy Medical Group
9394 Big Horn Blvd Fl 2, Elk Grove, CA 95758

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: May 18, 2026
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)
Enrollment Status: Completed
Publish Date: May 21, 2025
Intervention Type: Drug
Study Drug: Rucaparib
Study Phase: Phase 2
View 4 Less Clinical Trials
Similar Doctors
Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

UC Davis Comprehensive Cancer Center

2279 45th St, 
Sacramento, CA 
 (8.7 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathan Riess is an Oncologist practicing medicine in Sacramento, California. Dr. Riess is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Thymic Epithelial Tumor, Bone Marrow Aspiration, and Gastrostomy.

Expertise in
32
conditions
Expertise in
32
conditions
Referral may be required

Office

4501 X St Ste 3016, 
Sacramento, CA 
 (8.7 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Tuscano is an Oncologist practicing medicine in Sacramento, California. Dr. Tuscano is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Burkitt Lymphoma, and Bone Marrow Aspiration.

Expertise in
19
conditions
Expertise in
19
conditions
Referral may be required

UC Davis Comprehensive Cancer Center

2279 45th St, 
Sacramento, CA 
 (8.7 miles away)
916-734-5959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Primo Lara is an Oncologist practicing medicine in Sacramento, California. Dr. Lara is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Prostate Cancer, Familial Prostate Cancer, Nephrectomy, and Orchiectomy.

Frequently Asked Questions about Dr. Delphine W. Ong

How do I make an appointment with Dr. Delphine W. Ong?

You can book an appointment with Dr. Delphine W. Ong by calling their office at 916-306-7951. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Delphine W. Ong a top-rated expert for Paget Disease of the Breast?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Delphine W. Ong is classified as an Distinguished expert for Paget Disease of the Breast, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Delphine W. Ong specialize in?

While Dr. Delphine W. Ong is a Oncology, they have specific expertise in Paget Disease of the Breast, Breast Cancer, and Inflammatory Breast Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ong's expertise for a condition
ConditionClose
    View All 38 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile